HuGE Literature Finder
|
||
Records 1-23
|
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Oncotarget 2016 Apr . Gansmo Liv B, Vatten Lars, Romundstad Pål, Hveem Kristian, Ryan Bríd M, Harris Curtis C, Knappskog Stian, Lønning Per |
|
MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
Scientific reports 2016 6 33153. Helwa Reham, Gansmo Liv B, Romundstad Pål, Hveem Kristian, Vatten Lars, Ryan Bríd M, Harris Curtis C, Lønning Per E, Knappskog Sti |
|
Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
The Prostate 2015 Dec . Kibel Adam S, Ahn Jiyoung, Isikbay Masis, Klim Aleksandra, Wu William S, Hayes Richard B, Isaacs William B, Daw E Warwi |
|
MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Cancer medicine 2015 Oct . Gansmo Liv B, Romundstad Pål, Birkeland Einar, Hveem Kristian, Vatten Lars, Knappskog Stian, Lønning Per Eyste |
|
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
International journal of cancer. Journal international du cancer 2015 Jul 137 (1): 96-103. Gansmo Liv B, Knappskog Stian, Romundstad Pål, Hveem Kristian, Vatten Lars, Lønning Per |
|
MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
Oncotarget 2015 May . Xue Li, Han Xiujuan, Liu Rongrong, Wang Ziming, Li Hecheng, Chen Qi, Zhang Peng, Wang Zhenlong, Chong T |
|
Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Urologic oncology 2013 Jan 31 (1): 74-81. Meyer Andreas, Coinac Irina, Bogdanova Natalia, Dubrowinskaja Natalia, Turmanov Nurzhan, Haubold Sabine, Schürmann Peter, Imkamp Florian, von Klot Christoph, Merseburger Axel S, Machtens Stefan, Bremer Michael, Hillemanns Peter, Kuczyk Markus A, Karstens Johann H, Serth Jürgen, Dörk Thi |
|
Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients.
Disease markers 2013 35 (6): 701-10. Cintra Hellen Silva, Pinezi Juliana Castro Dourado, Machado Graziella Dias Pinheiro, de Carvalho Gustavo Moura, Carvalho Ana Terra Silva, dos Santos Thalles Eduardo Dias, Marciano Ricardo Duarte, Soares Renata de Bastos Ascen |
|
Meta-analysis of Associations between the MDM2-T309G Polymorphism and Prostate Cancer Risk.
Asian Pacific journal of cancer prevention : APJCP 2012 13 (9): 9. Chen T, Yi SH, Liu XY, Liu ZG |
|
Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis.
International journal of urology : official journal of the Japanese Urological Association 2012 Oct 19 (10): 914-20. Liu Guoyuan, Jiang Deke, Shen Suqin, Yu Lo |
|
Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?
Urologic oncology 2012 Sep 30 (5): 555-61. Mandal Raju Kumar, Mittal Rama De |
|
The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.
Asian journal of andrology 2012 Sep 14 (5): 726-31. Yang Jie, Gao Wen, Song Ning-Hong, Wang Wei, Zhang Jie-Xiu, Lu Pei, Hua Li-Xin, Gu M |
|
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
European journal of cancer (Oxford, England : 1990) 2011 Nov . Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lønning PE |
|
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
PloS one 2011 6 (2): e16914. Campa Daniele, Hüsing Anika, Stein Angelika, Dostal Lucie, Boeing Heiner, Pischon Tobias, Tjønneland Anne, Roswall Nina, Overvad Kim, Østergaard Jane Nautrup, Rodríguez Laudina, Sala Núria, Sánchez Maria-José, Larrañaga Nerea, Huerta José María, Barricarte Aurelio, Khaw Kay-Tee, Wareham Nicholas, Travis Ruth C, Allen Naomi E, Lagiou Pagona, Trichopoulou Antonia, Trichopoulos Dimitrios, Palli Domenico, Sieri Sabina, Tumino Rosario, Sacerdote Carlotta, van Kranen Henk, Bueno-de-Mesquita H Bas, Hallmans Göran, Johansson Mattias, Romieu Isabelle, Jenab Mazda, Cox David G, Siddiq Afshan, Riboli Elio, Canzian Federico, Kaaks Rudo |
|
Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Nov 16 (21): 5244-51. Sun Tong, Lee Gwo-Shu Mary, Oh William K, Pomerantz Mark, Yang Ming, Xie Wanling, Freedman Matthew L, Kantoff Philip |
|
Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese.
Cancer genetics and cytogenetics 2010 Oct 202 (2): 76-81. Xu Bin, Xu Zheng, Cheng Gong, Min Zhi-Chao, Mi Yuanyuan, Zhang Zhi-zhong, Tao Jun, Li Peng-Chao, Wang Mei-Lin, Tang Jia-Lin, Zhang Zheng-Dong, Zhang Wei, Wu Hong-Fei, Feng Ning-Han, Hua Li-X |
|
p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population.
Urologia internationalis 2010 85 (4): 401-5. Xu Bin, Mi Yuan-Yuan, Min Zhi-Chao, Cheng Gong, Tong Na, Tao Jun, Li Peng-Chao, Wang Mei-Lin, Tang Jia-Lin, Zhang Zheng-Dong, Song Ning-Hong, Zhang Wei, Wu Hong-Fei, Feng Ning-Han, Hua Li-X |
|
Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
The Journal of urology 2009 Apr 181 (4): 1907-12. Hirata Hiroshi, Hinoda Yuji, Kikuno Nobuyuki, Suehiro Yutaka, Shahryari Varahram, Ahmad Ardalan E, Tabatabai Z Laura, Igawa Mikio, Dahiya Rajv |
|
A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.
Carcinogenesis 2008 Sep 29 (9): 1758-64. Woelfelschneider Andreas, Popanda Odilia, Lilla Carmen, Linseisen Jakob, Mayer Claudia, Celebi Oktay, Debus Jürgen, Bartsch Helmut, Chang-Claude Jenny, Schmezer Pet |
|
Association between polymorphisms in cell cycle genes and advanced prostate carcinoma.
The Prostate 2008 Aug 68 (11): 1179-86. Kibel Adam S, Jin Carol H, Klim Aleksandra, Luly Jason, A Roehl Kimberly, Wu William S, Suarez Brian |
|
Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.
British journal of cancer 2008 Jul 99 (1): 78-82. Stoehr R, Hitzenbichler F, Kneitz B, Hammerschmied C G, Burger M, Tannapfel A, Hartmann |
|
A Systematic Review and Meta-Analysis of Three Gene Variants Association with Risk of Prostate Cancer: An Update.
Urology journal 0 12 (3): 2138-47. Chen Yu, Zhong Huan, Gao Jian-Guo, Tang Jian-Er, Wang Rongjia |
|
No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.
Urologic oncology 0 29 (3): 319-23. Jaboin Jerry J, Hwang Misun, Perez Carmen A, Cooper Calvin, Chen Heidi, Ye Chuanzhong, Cai Qiuyin, Wills Marcia L, Lu |
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 13, 2019
- Content source: